Lexicon Pharmaceuticals (LXRX) Posts Narrower than Expected Q2 Loss of 5c/Sh.
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $1.92 +1.59%
Revenue Growth %: -86.1%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: -86.1%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q2 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $555 thousand versus the consensus estimate of $350 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- Schwab's May activity shows margin loans nearly double
- United Community Banks sells equipment finance unit for $1.9 billion
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
